腹腔镜左半肝切除术中不同肝血流阻断方式对原发性肝癌患者血清HMGB1、TK1、H2AFX水平及免疫功能的影响
收稿日期: 2026-01-08
网络出版日期: 2026-04-29
基金资助
山东省医药卫生科技发展计划项目(202203070209)
The influence of different hepatic blood flow occlusion methods during laparoscopic left hemihepatectomy on serum HMGB1, TK1, H2AFX levels and immune function in patients with primary liver cancer
Received date: 2026-01-08
Online published: 2026-04-29
目的 探讨腹腔镜左半肝切除术中不同肝血流阻断方式对原发性肝癌患者血清高迁移率族蛋白B1(HMGB1)、胸苷激酶1(TK1)、H2A组蛋白家族成员X(H2AFX)水平及免疫功能的影响。 方法 选择2022年1月至2023年5月期间康复大学青岛中心医院收治的141例原发性肝癌患者(腹腔镜左半肝切除),依据其术中实际采用的肝血流阻断方式分为A组(Pringle法,n = 57)、B组(鞘内解剖法,n = 45)与C组(联合静脉阻断法,n = 39)。3组术后均进行随访,随访截至2025年5月31日或患者死亡。比较3组围手术期相关指标,比较术前和术后3 d 3组肝功能[丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)、前白蛋白(PA)、碱性磷酸酶(ALP)]、免疫功能(CD3+、CD4+、CD8+、CD4+/CD8+)、血清HMGB1、TK1、H2AFX水平情况,比较3组随访期间术后并发症发生情况及总生存期(OS)、无进展生存期(PFS)。 结果 3组间的术中出血量及术后恢复时间(包括排气、下床、进食流质及住院时间)C组< B组< A组(P < 0.05)。较术前,3组术后3 d ALT、AST、TBIL、ALP、CD8+升高,且A组> B组> C组;PA、CD3+、CD4+、CD4+/CD8+下降,A组< B组< C组,差异有统计学意义(P < 0.05)。相较术前,3组术后3 d血清HMGB1、TK1、H2AFX水平升高,且C组< B组< A组(P < 0.05)。随访期间,C组并发症发生率低于A、B组,差异有统计学意义(P < 0.05),B组与A组并发症比较差异无统计学意义(P > 0.05)。3组总OS比较差异有统计学意义(χ2 = 7.189,P = 0.028),其中C组OS优于A组(HR = 0.517,95%CI:0.325 ~ 0.824)和B组(HR = 0.621,95%CI:0.387 ~ 0.996);3组PFS比较差异有统计学意义(χ2 = 7.493,P = 0.024),其中C组PFS优于A组(HR = 0.509,95%CI:0.319 ~ 0.814)和B组(HR = 0.644,95%CI:0.400 ~ 1.038)。 结论 联合静脉阻断法相较于单纯Pringle法或单纯鞘内解剖法,能更有效地抑制腹腔镜左半肝切除术引起的血清HMGB1、TK1、H2AFX水平升高,减轻肝功能损伤和免疫功能紊乱,减少术后并发症,并获得更优的近期疗效与远期生存。
史成宇 , 孟飞飞 , 徐冰 , 郭成 . 腹腔镜左半肝切除术中不同肝血流阻断方式对原发性肝癌患者血清HMGB1、TK1、H2AFX水平及免疫功能的影响[J]. 实用医学杂志, 2026 , 42(9) : 1552 -1560 . DOI: 10.3969/j.issn.1006-5725.2026.09.009
Objective To investigate the effects of different hepatic blood flow occlusion methods on the serum levels of high mobility group protein B1 (HMGB1), thymidine kinase 1 (TK1), H2A histone family member X (H2AFX), and the immune function in patients with primary liver cancer during laparoscopic left hemihepatectomy. Methods A total of 141 patients diagnosed with primary hepatocellular carcinoma who underwent laparoscopic left hemihepatectomy at the Rehabilitation University Qingdao Central Hospital from January 2022 to May 2023 were selected. According to the actual hepatic blood-flow occlusion technique employed during the surgery, they were divided into three groups: Group A (Pringle maneuver, n = 57), Group B (intrahepatic sheath dissection method, n = 45), and Group C (combined venous occlusion method, n = 39). All three groups were followed up post-operatively until May 31, 2025, or until the patient's death. Perioperative indicators were compared among the groups. Liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), prealbumin (PA), alkaline phosphatase (ALP)], immune function (CD3+, CD4+, CD8+, CD4+/CD8+ ratio), and serum levels of HMGB1, TK1, and H2AFX were evaluated preoperatively and on the third postoperative day. Moreover, the incidence of postoperative complications during the follow-up period, overall survival (OS), and progression-free survival (PFS) were compared among the three groups. Results Significant differences were detected among the three groups in terms of intraoperative blood loss and postoperative recovery times (including time to first flatus, ambulation, initiation of liquid diet, and hospital stay). Group C exhibited the most favorable outcomes, followed by Group B, and then Group A (C < B < A, P < 0.05). When compared to preoperative levels, on the third postoperative day, the levels of ALT, AST, TBIL, ALP, and CD8+ increased in all groups. Group A had the highest levels, followed by Group B, and Group C had the lowest (A > B > C, P < 0.05). Conversely, the levels of PA, CD3+, CD4+, and the CD4+/CD8+ ratio decreased. Group A had the lowest values, followed by Group B, and Group C had the highest (A < B < C, P < 0.05). Compared with preoperative levels, the serum levels of HMGB1, TK1, and H2AFX increased on the third postoperative day in all groups. The smallest increase was observed in Group C, followed by Group B, and the greatest increase was in Group A (C < B < A, P < 0.05). During the follow-up period, the complication rate in Group C was significantly lower than those in Groups A and B (P < 0.05), while there was no significant difference between Groups A and B (P > 0.05). A statistically significant difference in overall OS was identified among the three groups (χ2 = 7.189, P = 0.028). Specifically, Group C had a superior OS compared to Group A (HR = 0.517, 95%CI: 0.325 - 0.824) and Group B (HR = 0.621, 95%CI: 0.387 - 0.996). Similarly, a statistically significant difference in PFS was found (χ2 = 7.493, P = 0.024), with Group C showing better PFS than Group A (HR = 0.509, 95%CI: 0.319 - 0.814) and Group B (HR = 0.644, 95%CI: 0.400 - 1.038). Conclusions Compared with the conventional Pringle maneuver or the intrahepatic sheath dissection method used alone, the combined venous occlusion method can more effectively suppress the postoperative elevation of serum HMGB1, TK1, and H2AFX levels induced by laparoscopic left hemihepatectomy. It can mitigate liver function impairment and immunological dysfunction, reduce postoperative complications, and achieve superior short-term efficacy and long-term survival outcomes.
| [1] | TAN E Y, DANPANICHKUL P, YONG J N, et al. Liver cancer in 2021: Global Burden of Disease study[J]. J Hepatol, 2025, 82(5): 851-860. doi: 10.1016/j.jhep.2024.10.031 . |
| [2] | RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606. doi: 10.1016/j.jhep.2022.08.021 . |
| [3] | LIU D, FANG J M, CHEN X Q. Clinical significance of half-hepatic blood flow occlusion technology in patients with hepatocellular carcinoma with cirrhosis[J]. World J Clin Cases, 2022, 10(24): 8547-8555. doi: 10.12998/wjcc.v10.i24.8547 . |
| [4] | CHEN S, HUANG C, LIAO G, et al. Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences[J]. Gut, 2023, 72(6): 1196-1210. doi: 10.1136/gutjnl-2022-328428 . |
| [5] | 古丽斯坦, 康书红, 谷申森. 区域性入肝血流阻断对腹腔镜肝切除术治疗原发性肝癌的近期疗效及安全性评价[J]. 临床和实验医学杂志, 2025, 24(1): 14-18. doi: 10.3969/j.issn.1671-4695.2025.01.004 . |
| [6] | ZHANG Y, REN H, LI J, et al. Elevated HMGB1 expression induced by hepatitis B virus X protein promotes epithelial-mesenchymal transition and angiogenesis through STAT3/miR-34a/NF-κB in primary liver cancer[J]. Am J Cancer Res, 2021, 11(2): 479-494. PMID: . |
| [7] | TAO J, WANG Z, SHI R, et al. ERK-USP9X-coupled regulation of thymidine kinase 1 promotes both its enzyme activity-dependent and its enzyme activity-independent functions for tumor growth[J]. Nat Struct Mol Biol, 2025, 32(5): 853-863. doi: 10.1038/s41594-024-01473-6 . |
| [8] | HU H, ZHONG T, JIANG S. H2AFX might be a prognostic biomarker for hepatocellular carcinoma[J]. Cancer Rep (Hoboken), 2023, 6(1): e1684. doi: 10.1002/cnr2.1684 . |
| [9] | HEIMBACH J K, KULIK L M, FINN R S, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380. doi: 10.1002/hep.29086 . |
| [10] | CHEN Z, ZHANG G, REN X, et al. Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer[J]. Cancer Res, 2023, 83(21): 3544-3561. doi: 10.1158/0008-5472.CAN-23-0193 . |
| [11] | 国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华肝脏病杂志, 2020, 28(2): 112-128. doi: 10.3760/cma.j.issn.1007-3418.2020.02.004 . |
| [12] | 孙彦浩, 周毅, 胡亿龙. 腹直肌面积及内脏脂肪分布对肝癌开腹根治术后手术切口感染风险的预测价值[J]. 实用医学杂志, 2025, 41(10): 1445-1452. doi: 10.3969/j.issn.1006-5725.2025.10.003 . |
| [13] | LIAO W, JEPSEN P, COUPLAND C, et al. Development and validation of personalised risk prediction models for early detection and diagnosis of primary liver cancer among the English primary care population using the QResearch? database: Research protocol and statistical analysis plan[J]. Diagn Progn Res, 2022, 6(1): 21. doi: 10.1186/s41512-022-00133-x . |
| [14] | LI H Y, JING Y M, SHEN X, et al. Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma[J]. World J Gastrointest Oncol, 2024, 16(9): 3913-3931. doi: 10.4251/wjgo.v16.i9.3913 . |
| [15] | LAPITZ A, AZKARGORTA M, MILKIEWICZ P, et al. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma[J]. J Hepatol, 2023, 79(1): 93-108. doi: 10.1016/j.jhep.2023.02.027 . |
| [16] | KIKUCHI M, IWAI T, NISHIDA M, et al. Assessment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome using different scanning approaches for the ultrasonographic evaluation of portal vein blood flow and hepatic artery resistive index in hematopoietic stem cell transplant recipients[J]. J Med Ultrason (2001), 2023, 50(4): 465-471. doi: 10.1007/s10396-023-01335-6 . |
| [17] | JINGHAN W, JIANYANG A, WENCONG M, et al. Totally laparoscopic associating simultaneous bile duct and portal vein ligation for planned hepatectomy for primary liver cancer: A case report[J]. J Med Case Rep, 2023, 17(1): 200. doi: 10.1186/s13256-023-03859-4 . |
| [18] | FICHTINGER R S, ALDRIGHETTI L A, HILAL M ABU, et al. Laparoscopic Versus Open Hemihepatectomy: The ORANGE II PLUS Multicenter Randomized Controlled Trial[J]. J Clin Oncol, 2024, 42(15): 1799-1809. doi: 10.1200/JCO.23.01019 . |
| [19] | FENG W, CHEN J, HUANG W, et al. HMGB1-mediated elevation of KLF7 facilitates hepatocellular carcinoma progression and metastasis through upregulating TLR4 and PTK2[J]. Theranostics, 2023, 13(12): 4042-4058. doi: 10.7150/thno.84388 . |
| [20] | LI Z, WU Z, YOU X, et al. Pan-cancer analysis reveals that TK1 promotes tumor progression by mediating cell proliferation and Th2 cell polarization[J]. Cancer Cell Int, 2024, 24(1): 329. doi: 10.1186/s12935-024-03515-x . |
| [21] | PRABHU K S, KUTTIKRISHNAN S, AHMAD N, et al. H2AX: A key player in DNA damage response and a promising target for cancer therapy[J]. Biomed Pharmacother, 2024, 175(1): 116663. doi: 10.1016/j.biopha.2024.116663 . |
| [22] | CHEN Y Z, XU D, JIA Y X, et al. HMGB1 orchestrates tumor-osteoclast crosstalk to drive bone metastasis in hepatocellular carcinoma[J]. Cell Death Dis, 2025, 16(1): 712. doi: 10.1038/s41419-025-08037-6 . |
| [23] | 邓金涛,许文斌,任建华,等.重组人HMGB1调控内皮细胞成血管作用的机制初探[J].器官移植,2023,14(3):397-403.doi: 10.3969/j.issn.1674-7445.2023.03.011 . |
| [24] | LI Q, ZHANG L, YANG Q, et al. Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners[J]. Cell Metab, 2023, 35(6): 912-927.e7. doi: 10.1016/j.cmet.2023.03.017 . |
| [25] | HU H, ZHONG T, JIANG S. H2AFX might be a prognostic biomarker for hepatocellular carcinoma[J]. Cancer Rep (Hoboken), 2023, 6(1): e1684. doi: 10.1002/cnr2.1684 . |
| [26] | 张浩楠, 张林枝, 高炜, 等. 免疫评分在肝癌患者中的预后研究[J]. 中国临床解剖学杂志, 2021, 39(1): 82-89. doi: 10.13418/j.issn.1001-165x.2021.01.016 . |
| [27] | 池育菁, 杨心怡, 朱月永, 等. 乙型肝炎和酒精对肝硬化肝癌的预后特征和影响因素分析[J]. 中国热带医学, 2025, 25(3): 289-296. doi: 10.13604/j.cnki.46-1064/r.2025.03.06 . |
| [28] | TAO J, WANG Z, SHI R, et al. ERK-USP9X-coupled regulation of thymidine kinase 1 promotes both its enzyme activity-dependent and its enzyme activity-independent functions for tumor growth[J]. Nat Struct Mol Biol, 2025, 32(5): 853-863. doi: 10.1038/s41594-024-01473-6 . |
/
| 〈 |
|
〉 |